Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
After filling its pipeline with Big Pharma-partnered antibody therapeutics, J&J darling Genmab has turned to a fellow European biotech for its latest foray into cancer immunotherapies.
Copenhagen-based Genmab is paying $54 million for three targets identified by Immatics’ Xpresident platform, as well as access to its T cell receptor discovery and engineering platform. Immatics — which is headquartered in Tuebingen, Germany and runs a subsidiary in Houston — is also in for $550 million in milestone payments and a co-promotion option.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.